485
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
STUDY OF THE EFFECT OF THE SUBSTANCE “ALFAMANKOR” ON HEPG2
CELLS
Khayrullaev D.K.
Gulyamov Sh.Sh.
Zakirova R.Yu.
Jumaboev F.R.
Sharipov A.T.
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
https://doi.org/10.5281/zenodo.17342878
Relevance:
Liver cancer, particularly hepatocellular carcinoma (HepG2), is one of the most
common cancers worldwide, with a high mortality rate. Current chemotherapeutic agents often have
significant side effects, and their effectiveness is limited. Therefore, the search for new, effective, and
less toxic compounds is considered a key area of research in oncology.
Main compounds, particularly biologically active substances containing metal ions, can disrupt
cellular redox homeostasis and activate apoptosis. The Tashkent Pharmaceutical Institute has
developed a complex compound based on alpha-lipoic acid, known as "Alfamankor" which has
specific antiproliferative and cytotoxic properties. Studying its effect on HepG2 cells may open up
new therapeutic options for the treatment of liver cancer.
Purpose of the study:
To evaluate the cytotoxic and antiproliferative effect of the complex
compound "Alfamankor " against human hepatocellular carcinoma cells (HepG2) in vitro, and to
determine its potential therapeutic value.
Materials and methods: Cell culture:
The human hepatocellular carcinoma cell line HepG2
was maintained in Dulbecco's modified medium (DMEM) supplemented with 10% FBS and 1%
penicillin-streptomycin at 37°C in a humidified incubator with 5% CO₂.
Cell viability analysis:
HepG2 cells were seeded at a density of 15,000 cells/well in 96-well
plates and incubated for 24 hours. The cells were then treated with Alfamankor at various
concentrations (50, 75, 100, 125, and 150 μM) for 24 hours. After incubation, cell viability was
assessed using the Cell Counting Kit-8 (CCK-8, Dojindo, Japan). Ten microliters of CCK-8 solution
were added to each well and incubated for another 3 hours at 37°C. Absorbance was measured at 450
nm using an ELMR-112 microplate reader (Scitek Global Co., Ltd.). Experiments were performed in
triplicate, and viability was calculated as a percentage relative to untreated control cells.
Results:
Effect of Alfamankor on HepG2 Cell Viability: The cytotoxicity of Alfamankor
against HepG2 cells was assessed after 24-hour exposure using the CCK-8 assay. Treatment with
Alfamankor resulted in a clear, dose-dependent reduction in cell viability, with an IC₅₀ value
calculated at approximately 36.8 μM. Significant cytotoxicity was observed at concentrations starting
at 50 μM, with cell viability consistently below 50%, indicating high anticancer efficacy in this
hepatocellular carcinoma cell line. This study evaluated the anticancer activity of Alfamankor against
the human hepatocellular carcinoma cell line HepG2, which demonstrated significant cytotoxic
potential, reflected by an IC₅₀ value of approximately 36.8 μM.
Conclusions:
The obtained results indicate that Alfamankor has potential therapeutic efficacy
in the treatment of liver cancer, especially considering its pronounced efficacy at lower micromolar
concentrations.
